Note: This document has been translated from the Japanese original for reference purpose only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Consolidated Financial Results
for the Nine Months Ended September 30, 2026
[Under Japanese GAAP]

November 12, 2026

Company name:	FINDEX Inc.
Listing:	Tokyo Stock Exchange
Securities code:	3649
URL:	https://findex.co.jp/en/index.html
Representative:	Teruo Aibara, President & CEO
Inquiries:	Takahiro Yazawa, Director & CFO
Telephone:	+81-3-6271-8958
Scheduled date to commence dividend payments:	N/A
Preparation of supplementary material on financial results:	Yes
Holding of financial results briefing:	No

1. Consolidated Financial Results for the Nine Months ended September 30, 2026 (From January 1, 2026, to September 30, 2026)

**Figures are rounded down to the nearest million yen, except share and per share data*

**"%" indicates year-on-year changes from the previous corresponding period*

(1) Consolidated Operating Results (Cumulative)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Nine months ended	JPY MM	%	JPY MM	%	JPY MM	%	JPY MM	%
September 30, 2026	4,297	(1.7)	985	(17.5)	1,034	(16.6)	639	(25.1)
September 30, 2025	4,372	1.5	1,195	6.2	1,240	9.5	853	2.6

(Note) Comprehensive income: Q3 FY2026: 602 million yen [(28.9%)], Q3 FY2025: 848 million yen [2.1%]

	Basic earnings per share	Diluted earnings per share
Nine months ended	JPY	JPY
September 30, 2026	26.19	-
September 30, 2025	33.72	-

(Note) Diluted earnings per share for the nine months ended September 30, 2025 and September 30, 2026 are not presented, as there were no potentially dilutive shares.

(2) Consolidated Financial Position

	Total assets	Net assets	Equity-to-asset ratio
As of	JPY MM	JPY MM	%
September 30, 2026	6,343	5,423	85.0
December 31, 2025	6,807	5,467	79.9

(Ref.) Equity amount: Q3 FY2026: 5,394 million yen, FY2025: 5,440 million yen

2. Cash Dividends

	Annual dividends per share				
	1st quarter	2nd quarter	3rd quarter	Year-end	Total
	JPY	JPY	JPY	JPY	JPY
Year ended December 31, 2025	–	8.00	–	14.00	22.00
Year ending December 31, 2026	–	13.00	–		
Year ending December 31, 2026 (Forecast)			–	14.00	27.00

(Note) Revisions to the forecast of cash dividends most recently announced: None

3. Consolidated Financial Forecasts for the Fiscal Year ending December 31, 2026 (From January 1, 2026, to December 31, 2026)

** Figures are rounded down to the nearest million yen, except share and per share data*
** "%" indicates year-on-year changes from the previous corresponding period*

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	JPY MM	%	JPY MM	%	JPY MM	%	JPY MM	%	JPY
Fiscal year ending December 31, 2026	6,209	1.6	1,829	2.2	1,889	2.6	1,302	3.6	53.34

(Note) Revisions to the consolidated financial forecast since the latest announcement: None

*Notes:

(1) Significant changes in the scope of consolidation during the period: None
Newly included companies: None, Newly excluded companies: None

(2) Application of Specific Accounting Methods for Quarterly Consolidated Financial Statements: None

(3) Changes in Accounting Policies, Changes in Accounting Estimates, and Restatement
(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None
(ii) Changes in accounting policies other than (i) above: None
(iii) Changes in accounting estimates: None
(iv) Restatement: None

(4) Number of issued shares (Common Shares)

	As of September 30, 2026	As of December 31, 2025
Number of shares outstanding at the end of the period (including treasury shares)	26,608,800	26,608,800
Number of treasury shares at the end of the period	2,180,979	2,200,265
	Nine months ended September 30, 2026	Nine months ended September 30, 2025
Average number of outstanding shares (cumulative for the nine months)	24,418,622	25,309,048

(Note) The number of treasury shares at the end of the period includes our shares held by Custody Bank of Japan, Ltd. (Trust Account E) 126,700 shares for Q3 FY2026, 132,200 shares for FY2025). The Company's shares held by Custody Bank of Japan, Ltd. (Trust Account) are included in the treasury share deducted in the calculation of the average number of outstanding shares during the period (130,749 shares for Q3 FY2026, 135,998 shares for Q3 FY2025).

*Review of this quarterly financial results report by a certified public accountant or audit firm: N/A

* Explanation on appropriate use of performance forecasts and other special notes:
The performance forecast described in this report is based on information that is available to the Group, as well as certain assumptions and estimates that are deemed to be reasonable, and we make no assurance that such descriptions prove to be correct. Actual figures may significantly differ due to various factors.

Attached Material

Index

1. Qualitative Information on Quarterly Consolidated Financial Results……. 2
(1) Explanation on Operating Results……..….... 2
(2) Explanation on the Financial Position ……..……... 5
(3) Explanation on Consolidated Financial Forecasts and Other Forward-looking Statements…… 5
2. Quarterly Consolidated Financial Statements and Significant Notes Thereto…….. 6
(1) Quarterly Consolidated Balance Sheet …… 6
(2) Quarterly Consolidated Statements of Income and Comprehensive Income …….. 7
Quarterly Consolidated Statement of Income, Cumulative…… 7
Quarterly Consolidated Statement of Comprehensive Income, Cumulative ……. 8
(3) Notes to the Quarterly Consolidated Financial Statements…….. 9
Notes on Segment Information etc…….…….…….....….... 9
Notes on Significant Changes in Shareholders' Equity ……..... 9
Notes on Going Concern Assumption……..... 9
Notes on the Quarterly Consolidated Statements of Cash Flows…….. 9
Additional Information...……..... 10
3. Supplementary Information ……. 11

1. Qualitative Information on Quarterly Consolidated Financial Results

(1) Explanation on Operating Results

For the cumulative third quarter of the current consolidated fiscal year, net sales reached 69.2% of the full-year forecast, progressing in line with historical levels (past five-year average of 69.8%). Given the seasonality of our Group's business, where net sales and profits tend to concentrate in the first and fourth quarters, we have left our full-year earnings forecast and dividend forecast unchanged.

Medical institutions continue to face a challenging business environment, as medical service fee revisions have not kept pace with rising personnel costs. On the other hand, promoting Medical DX remains a key national policy, as highlighted by the Ministry of Health, Labour and Welfare's "Policy for Promoting Healthcare Informatization" (implemented in October 2026), which aims for nearly 100% adoption of electronic medical record (EMR) systems capable of sharing medical data by the end of 2030. In this environment, our Group's solutions and services continue to be utilized as essential infrastructures supporting daily clinical practices.

In our core Medical Business segment, we had initially planned for a 4.2% year-on-year decrease in full-year net sales, reflecting an off-peak phase in the system renewal cycle of university hospitals and other large institutions. However, driven by the expansion of cloud services—including electronic prescription-related solutions—the actual decline in revenue was limited to 1.2%, helping offset shortfalls against targets in the Public Sector Business and Health Tech Business segments.

Because our Group's expenses, particularly personnel costs, are incurred evenly throughout the year, the progress rate for profits at the third quarter typically trails that of net sales. Furthermore, alongside planned salary increases, investments in company-wide infrastructure—such as AI services aimed at enhancing operational efficiency and boosting productivity—have expanded, bringing the progress rate for operating profit to 53.9%. Growth investments, including the recruitment of specialized talent and R&D, are proceeding as scheduled.

Profit attributable to owners of parent includes an impairment loss on investment securities of ¥106,964 thousand recorded as an extraordinary loss, resulting from a revaluation of certain unlisted shares held by the company based on a revised valuation of the investee. This is a non-cash, one-time accounting loss and has no impact on our core operational activities. Should the valuation of the investee recover by the end of the current fiscal year, there is a possibility that this impairment will be reversed.

The consolidated financial results for the nine months ended September 30, 2026 are as follows.

(JPY in thousands)

	Nine months ended September 30, 2025	Nine months ended September 30, 2026	Change (amount)	Change (%)	Progress rate (%)
Net sales	4,372,934	4,297,983	(74,951)	(1.7%)	69.2%
Operating profit	1,195,164	985,895	(209,268)	(17.5%)	53.9%
Ordinary profit	1,240,391	1,034,631	(205,759)	(16.6%)	54.8%
Profit attributable to owners of the parent	853,470	639,507	(213,963)	(25.1%)	49.1%

In the first nine months of the fiscal year ending December 31, 2026, consolidated net sales were ¥4,297,983 thousand (down 1.7% YoY), operating profit was ¥985,895 thousand (down 17.5% YoY), Ordinary profit was ¥1,034,631 thousand (down 16.6% YoY), and profit attributable to owners of the parent was ¥639,507 thousand (down 25.1%).

Consolidated results by segment for the first nine months of the current fiscal year are as follows.

≪Medical Business≫

(JPY in thousands)

	Nine months ended September 30, 2025	Nine months ended September 30, 2026	Change (amount)	Change (%)
Net sales	4,015,682	3,967,442	(48,240)	(1.2%)
Operating profit	1,217,591	1,106,073	(111,518)	(9.2%)

Financial results for this segment were net sales of ¥3,967,442 thousand (down 1.2% YoY) and operating profit of ¥1,106,073 thousand (down 9.2% YoY). For the current fiscal year, a 4.2% YoY decline in full-year net sales

had been planned due to an off-peak phase in the system renewal cycle of key clients, such as university hospitals and large-scale hospitals. However, cloud services—including HPKI secondary electronic certificates related to electronic prescriptions—performed strongly, limiting the rate of revenue decline to just 1.2%. The decrease in operating profit was primarily driven by higher personnel expenses (salaries) and upfront investments in company-wide shared systems, such as AI services aimed at enhancing operational efficiency.

In the first nine months of the current consolidated fiscal year, we carried out new implementations, additional implementations, or system upgrades across 41 hospitals and 94 clinics. Driven by expanded sales of cloud services and growth in maintenance services, recurring revenue for this segment rose to 36% of net sales (compared to 33% in the same period of the previous fiscal year).

Looking ahead, replacement demand for electronic medical records (EMR) and related systems is growing in the clinic sector—particularly among ophthalmology clinics—and is expected to contribute to earnings from the next fiscal year onward. In addition, through products and services compatible with the government-promoted Electronic Medical Record Information Sharing Service, we are advancing business expansion by contributing to regional medical coordination. Furthermore, "CocktailAI", a generative AI solution provided by our subsidiary Fitting Cloud Inc., has seen steady growth in the number of adopting facilities, supported by strong demand for labor-saving solutions in hospital administration.

≪Public Sector Business≫

(JPY in thousands)

	Nine months ended September 30, 2025	Nine months ended September 30, 2026	Change (amount)	Change (%)
Net sales	295,358	265,835	(29,523)	(10.0%)
Operating profit	113,556	42,082	(71,474)	(62.9%)

This segment operates a recurring-revenue business providing "DocuMaker Office", a SaaS-based document management solution for local governments and medical institutions. Since the service launch, cumulative active implementations have reached 67 for local governments and 15 for medical institutions, covering approximately 49,900 total users, while maintaining a churn rate of zero (zero cancellations).

In the first nine months of the current consolidated fiscal year, 12 new implementations for local governments and 2 for medical institutions went live. As a result, net sales totaled ¥265,835 thousand (down 10.0% YoY) and operating profit came to ¥42,082 thousand (down 62.9% YoY). The decline in revenue was due to the reaction to a large-scale project recorded in the first quarter of the previous fiscal year; however, the cumulative rate of revenue decline has narrowed to 10.0% from 29.1% as of the end of the second quarter. The decrease in operating profit was primarily driven by headcount additions—such as system engineers dedicated to local government clients—and system development to expand order intake, alongside investments in company-wide shared systems aimed at improving operational efficiency.

Among the local governments, we secured orders for six new projects through agency channels during the third quarter, steadily building up the order backlog heading into the next fiscal year. Negotiations for multiple large-scale projects slated for the next fiscal year and beyond are also progressing. Among the medical institutions, in addition to ongoing implementation work targeting go-lives within this year, projects scheduled to launch in the next fiscal year as well as new inquiries are progressing steadily.

≪Health Tech Business≫

(JPY in thousands)

	Nine months ended September 30, 2025	Nine months ended September 30, 2026	Change (amount)	Change (%)
Net sales	61,892	64,705	2,813	4.5%
Operating loss	(135,984)	(162,260)	(26,276)	-

This segment consists of the Medical Data Platform Business and the Medical Device Business.

The Medical Data Platform Business comprises two types of operations: (1) Non-certified contract services, which process and analyze medical record data upon individual requests from academic researchers; and (2) New operations, in which we process large volumes of electronic medical record (EMR) data as an "Entrusted Certified Medical Information Handler" under the Next Generation Medical Infrastructure Act (Note 1).

Operating results for this segment were net sales of ¥64,705 thousand (up 4.5% YoY) and an operating loss of ¥162,260 thousand (compared to an operating loss of ¥135,984 thousand in the same period of the previous fiscal year).

[Medical Data Platform Business]

Regarding the new operations, the Company operates as an "Entrusted Certified Medical Information Handler" for FAST-HDJ, one of the four entities certified by the national government as a "Certified Producer" under the Next Generation Medical Infrastructure Act. Currently in the pre-operational preparatory phase, we are advancing the establishment of the Operations Center (a facility for medical data utilization), for which a lease agreement was signed in May, alongside securing specialized talent responsible for data analysis. We are proceeding with the review procedures necessary to commence facility operations, with operational launch scheduled for the beginning of the next fiscal year. Full-scale earnings contributions are expected thereafter.

[Medical Device Business]

The gaze analyzing perimeter *GAP* (Note 2) (a medical device for ophthalmology) and *GAP-screener* (Note 3) (a medical device for health screening facilities) are wearable medical devices that eliminate the need for a darkroom and enable fast visual field testing with minimal patient burden. Domestic sales volume during the cumulative third quarter consolidated period was one unit. Overseas, our distributor network has expanded to 72 companies across regions including Asia and South America. We secured a bulk order of 50 units from an overseas distributor for Europe, South America, and other markets; shipments commenced sequentially in September, and customer inspections were completed in October, with revenue set to be recognized in the fourth quarter. In addition, we began shipments to Thailand, initiating expansion across the ASEAN region. Domestically, we are reinforcing our sales framework by offering maintenance service plans and introducing incentive plans for distributors.

(Note 1) Next Generation Medical Infrastructure Act: The official name is the "Act on Anonymously Processed Medical Information and Pseudonymized Medical Information for the Purpose of Research and Development in the Medical Field". This law promotes the utilization of medical data by allowing secondary use, such as for new drug development, after processing personal information, including clinical and physical data, so that individuals cannot be identified.

(Note 2) Gaze Analyzing Perimeter, *GAP* (Notification No. of medical device manufacturing and sales 38B2X10003000002)

(Note 3) Gaze Analyzing Perimeter, *GAP-screener* (Notification No. of medical device manufacturing and sales 38B2X10003000003)

(2) Explanation on the Financial Position

Status of Assets, Liabilities, and Net assets

(JPY in thousands)

	As of December 31, 2025	As of September 30, 2026	Change in Amount
Assets	6,807,858	6,343,698	(464,159)
Liabilities	1,340,763	920,343	(420,420)
Net Assets	5,467,095	5,423,355	(43,739)

Total assets as of the end of the third quarter of the current consolidated fiscal year amounted to ¥6,343,698 thousand, a decrease of ¥464,159 thousand from the end of the previous consolidated fiscal year. This was mainly due to a decrease in current assets of ¥417,767 thousand, primarily reflecting decreases of ¥62,755 thousand in cash and deposits and ¥382,072 thousand in accounts receivable–trade and contract assets.

Liabilities totaled ¥920,343 thousand, a decrease of ¥420,420 thousand from the end of the previous consolidated fiscal year. This was mainly attributable to a decrease in current liabilities of ¥418,126 thousand, primarily due to a ¥312,960 thousand decrease in income taxes payable.

Net assets amounted to ¥ 5,423,355 thousand, a decrease of ¥43,739 thousand from the end of the previous consolidated fiscal year. This was mainly due to a decrease of ¥39,444 thousand in valuation difference on available-for-sale securities, resulting in a decrease in accumulated other comprehensive income.

(3) Explanation on Consolidated Financial Forecasts and Other Forward-looking Statements

There are no changes at this time to the consolidated financial results forecasts for the fiscal year ending December 31, 2026, announced in the financial results released on February 12, 2026. If any revisions to the forecasts become necessary, the Group will promptly disclose them.

2. Quarterly Consolidated Financial Statements and Significant Notes Thereto

(1) Quarterly Consolidated Balance Sheet

(JPY in thousands)

	As of December 31, 2025	As of September 30, 2026
Assets		
Current assets		
Cash and deposits	1,678,886	1,616,130
Accounts receivable - trade, and contract assets	1,787,025	1,404,952
Merchandise and finished goods	164,166	170,715
Work in process	7,232	4,414
Raw materials and supplies	19,964	17,809
Other	86,397	111,882
Total current assets	3,743,671	3,325,903
Non-current assets		
Property, plant and equipment	85,981	95,807
Intangible assets		
Software	299,227	287,825
Other	344	344
Total intangible assets	299,571	288,169
Investments and other assets	2,678,633	2,633,818
Total non-current assets	3,064,186	3,017,795
Total assets	6,807,858	6,343,698
Liabilities		
Current liabilities		
Accounts payable - trade	36,090	28,945
Accounts payable - other	127,991	101,437
Income taxes payable	345,067	32,106
Other	517,400	445,934
Total current liabilities	1,026,550	608,424
Non-current liabilities		
Provision for share awards	314,130	311,679
Other	83	239
Total non-current liabilities	314,213	311,918
Total liabilities	1,340,763	920,343
Net assets		
Shareholders' equity		
Share capital	254,259	254,259
Capital surplus	225,785	226,792
Retained earnings	6,755,228	6,731,957
Treasury shares	(1,752,311)	(1,737,081)
Total shareholders' equity	5,482,962	5,475,927
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	(42,005)	(81,450)
Total accumulated other comprehensive income	(42,005)	(81,450)
Non-controlling interests	26,138	28,878
Total net assets	5,467,095	5,423,355
Total liabilities and net assets	6,807,858	6,343,698

(2) Quarterly Consolidated Statements of Income and Comprehensive Income

(Quarterly Consolidated Statement of Income, Cumulative)

(JPY in thousands)

	Nine months ended September 30, 2025	Nine months ended September 30, 2026
Net sales	4,372,934	4,297,983
Cost of sales	1,559,761	1,542,099
Gross profit	2,813,172	2,755,883
Selling, general and administrative expenses	1,618,008	1,769,988
Operating profit	1,195,164	985,895
Non-operating income		
Interest income	36,936	38,143
Foreign exchange gains	—	8,530
Subsidy income	5,509	894
Royalty income	1,660	—
Other	2,645	1,168
Total non-operating income	46,752	48,736
Non-operating expenses		
Commission for purchase of treasury shares	1,524	—
Other	1	—
Total non-operating expenses	1,525	—
Ordinary profit	1,240,391	1,034,631
Extraordinary losses		
Loss on valuation of investment securities	—	106,964
Total extraordinary losses	—	106,964
Profit before income taxes	1,240,391	927,666
Income taxes - current	371,526	303,048
Income taxes - deferred	1,361	(17,628)
Total income taxes	372,887	285,419
Profit	867,503	642,247
Profit attributable to non-controlling interests	14,032	2,740
Profit attributable to owners of parent	853,470	639,507

(Quarterly Consolidated Statement of Comprehensive Income, Cumulative)

(JPY in thousands)

	Nine months ended September 30, 2025	Nine months ended September 30, 2026
Profit	867,503	642,247
Other comprehensive income		
Valuation difference on available-for-sale securities	(19,190)	(39,444)
Total other comprehensive income	(19,190)	(39,444)
Comprehensive income	848,313	602,803
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	834,280	600,062
Comprehensive income attributable to non-controlling interests	14,032	2,740

(3) Notes to the Quarterly Consolidated Financial Statement

(Notes on Segment Information etc.)

[Segment Information]

Sales and Profit or Loss by Reportable Segment

Nine Months ended September 30, 2025 (From January 1, 2025, to September 30, 2025)

(JPY in thousands)

	Reportable segments				Reported amount for consolidated financial statement (Note)
	Medical Business	Public Sector Business	Health Tech Business	Sub total	
Net Sales					
Sales to external customers	4,015,682	295,358	61,892	4,372,934	4,372,934
Intersegment sales or transfers	—	—	—	—	—
Total	4,015,682	295,358	61,892	4,372,934	4,372,934
Segment profit (loss)	1,217,591	113,556	(135,984)	1,195,164	1,195,164

(Note) Aggregated amount of segment income or loss equals amount of operating profit reported for consolidated financial statements.

Nine Months ended September 30, 2026 (From January 1, 2026, to September 30, 2026)

(JPY in thousands)

	Reportable segments				Reported amount for consolidated financial statement (Note)
	Medical Business	Public Sector Business	Health Tech Business	Sub total	
Net Sales					
Sales to external customers	3,967,442	265,835	64,705	4,297,983	4,297,983
Intersegment sales or transfers	—	—	—	—	—
Total	3,967,442	265,835	64,705	4,297,983	4,297,983
Segment profit (loss)	1,106,073	42,082	(162,260)	985,895	985,895

(Note) Aggregated amount of segment income or loss equals amount of operating profit reported for consolidated financial statements.

(Notes on Significant Changes in Shareholders' Equity): N/A

(Notes on Going Concern Assumption): N/A

(Notes on the Quarterly Consolidated Statements of Cash Flows)

The quarterly consolidated statement of cash flows for the nine months ended September 30, 2026 has not been prepared. Depreciation and amortization, and amortization of software intended for sale, for the nine-month period are as follows.

(JPY in thousands)

	Nine months ended September 30, 2025	Nine months ended September 30, 2026
Depreciation	26,200	30,738
Amortization of software	201,871	198,914

【Additional Information】

(Accounting Treatment for Employee Stock Ownership Plan, J-ESOP)

the Board of Directors meeting held on October 29, 2015, the Company resolved to adopt an employee stock ownership plan (referred to as J-ESOP) as an incentive plan to grant Company shares purchased from the market to employees in order to more closely link the Company's share price and earnings with employee compensation and to boost the motivation and morale of employees to improve the share price and earnings by sharing the economic benefits with shareholders.

Accordingly, Trust & Custody Services Bank, Ltd. (trust account E) (now Custody Bank of Japan, Ltd. (trust account E)) acquired 194,200 shares of the Company's stock between November 13, 2015 and November 26, 2015.

Regarding accounting treatment for the J-ESOP, we have applied the gross method to record trust assets and liabilities as corporate assets and liabilities on the consolidated balance sheet in accordance with the Practical Solution on Transactions of Delivering the Company's Own Stock to Employees etc. through Trusts (PITF No. 30, March 26, 2015).

The treasury stock held by Custody Bank of Japan, Ltd. (trust account E) is shown as treasury shares in the net assets section of the quarterly consolidated balance sheet. The amount recorded at the end of the previous fiscal year was ¥101,983 thousand and the number of shares was 132,200. The amount recorded at the end of the third quarter of the current fiscal year was ¥97,740 thousand and the number of shares was 126,700.

3. Supplementary Information

(1) Transition of Significant Financial Key Performance Indicators

(JPY in thousands, except per share amounts)

	Nine months ended September 30, 2025	Nine months ended September 30, 2026	Fiscal year ended December 31, 2025
Net sales	4,372,934	4,297,983	6,109,941
Operating profit	1,195,164	985,895	1,790,029
Ordinary profit	1,240,391	1,034,631	1,840,735
Profit	867,503	642,247	1,278,403
Profit attributable to owners of non-controlling interests	14,032	2,740	21,432
Profit attributable to owners of parent	853,470	639,507	1,256,970
Comprehensive income	848,313	602,803	1,250,714
Net assets	5,302,266	5,423,355	5,467,095
Total assets	6,328,172	6,343,698	6,807,858
Net assets per share (yen)	214.02	220.83	222.91
Basic earnings per share (yen)	33.72	26.19	50.07

(2) Production, Order and Sales

1) Actual Result of Production for Q3 FY2026 (Cumulative Amount)

Business segment	Production (JPY in thousands)	YoY (%)
Medical Business	1,134,922	102.3
Public Sector Business	104,071	112.3
Health Tech Business	106,668	105.6
Total	1,345,662	103.3

(Note) Figures above is calculated by total manufacturing cost for the current quarter.

2) Order Status for Q3 FY2026 (Cumulative Amount)

Business segment	Order received (JPY in thousands)	YoY (%)	Order backlog (JPY in thousands)	YoY (%)
Medical Business	2,753,874	85.1	1,986,196	112.9
Public Sector Business	140,079	95.8	108,286	96.1
Health Tech Business	60,805	98.3	30,000	253.8
Total	2,954,759	85.8	2,124,483	112.8

3) Sales Result for Q3 FY2026 (Cumulative Amount by Segments, Solutions, and Channels)

Segment, solution, channel	Sales amount (JPY in thousands)	Ratio (%)	YoY (%)
Medical Business			
On-premises software	2,096,356	48.8	96.9
[of via distributors]	[465,546]		
Support	1,297,764	30.2	101.9
[of via distributors]	[415,234]		
Cloud services	127,673	3.0	218.8
Consulting	19,650	0.4	26.7
Hardware	243,145	5.7	79.4
Other	182,851	4.2	129.9
Public Sector Business			
Cloud services	265,330	6.2	90.0
[of via distributors]	[51,722]		
Other	505	0.0	72.9
Health Tech Business			
Medical devices	15,455	0.4	25.0
Medical data	49,250	1.1	-
Total	4,297,983	100.0	98.3

Note: In order to more appropriately reflect changes in the Group's business structure, product and service categories have been reorganized effective from the beginning of the first quarter of the current consolidated fiscal year. Year-on-year comparisons are based on figures recalculated in accordance with the revised classification.